Clinical trial JK08.1.01
A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients with Unresectable Locally Advanced or Metastatic Cancer (JK08.1.01)
| Organ | Multiple |
|---|---|
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1/2 |
| Academic trial | Non |
| Sponsor | Salubris Biotherapeutics, Inc. |
| EudraCT Identifier | 2022-000339-21 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05620134 |
| Last update |